Prophylactic treatment in Sweden - overtreatment or optimal model?

被引:30
作者
Ljung, RCR [1 ]
机构
[1] Malmo Univ Hosp, Univ Lund, Dept Paediat, S-20502 Malmo, Sweden
[2] Malmo Univ Hosp, Univ Lund, Dept Coagulat Disorders, S-20502 Malmo, Sweden
关键词
haemophilia A; haemophilia B; factor VIII; factor IX; prophylaxis;
D O I
10.1046/j.1365-2516.1998.440409.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/2 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level >1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.
引用
收藏
页码:409 / 412
页数:4
相关论文
共 22 条
[1]   FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII [J].
ADDIEGO, J ;
KASPER, C ;
ABILDGAARD, C ;
HILGARTNER, M ;
LUSHER, J ;
GLADER, B ;
ALEDORT, L .
LANCET, 1993, 342 (8869) :462-464
[2]  
AHLBERG A, 1965, ACTA ORTHOPAEDICA S, V77
[3]   A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].
ALEDORT, LM ;
HASCHMEYER, RH ;
PETTERSSON, H ;
EIBL, H ;
GILBERT, M ;
HILGARTNER, M ;
KUNSHACK, M ;
LARRIEU, MJ ;
LEVINE, P .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399
[4]  
BERNTORP E, HAEMOPHILIA S1, V1, P3
[5]  
BOHN R, 1994, 21 INT C WORLD FED H
[6]  
BRACKMANN HH, 1992, HAEMOSTASIS, V22, P251
[7]   Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A [J].
Carlsson, M ;
Berntorp, E ;
Bjorkman, S ;
Lethagen, S ;
Ljung, R .
HAEMOPHILIA, 1997, 3 (02) :96-101
[8]  
CARLSSON N, 1993, EUR J HAEMATOL, V51, P247
[9]   The impact of prophylactic treatment on children with severe haemophilia [J].
Liesner, RJ ;
Khair, K ;
Hann, IM .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :973-978
[10]   IMPLANTABLE CENTRAL VENOUS CATHETER FACILITATES PROPHYLACTIC TREATMENT IN CHILDREN WITH HEMOPHILIA [J].
LJUNG, R ;
PETRINI, P ;
LINDGREN, AK ;
BERNTORP, E .
ACTA PAEDIATRICA, 1992, 81 (11) :918-920